

Product datasheet for **TL320544V**

TAK1 (MAP3K7) Human shRNA Lentiviral Particle (Locus ID 6885)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	TAK1 (MAP3K7) Human shRNA Lentiviral Particle (Locus ID 6885)
Locus ID:	6885
Synonyms:	CSCF; FMD2; MEKK7; TAK1; TGF1a
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	MAP3K7 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_003188 , NM_145331 , NM_145332 , NM_145333 , NM_003188.1 , NM_003188.2 , NM_003188.3 , NM_145331.1 , NM_145331.2 , NM_145332.1 , NM_145332.2 , NM_145333.2 , BC017715 , BC017715.2 , BM172351 , NM_145333.3 , NM_145332.3 , NM_003188.4 , NM_145331.3
UniProt ID:	O43318
Summary:	The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).